All data are based on the daily closing price as of December 5, 2024
s

ST Pharm

237690.KQ
61.71 USD
0.15
+0.24%

Overview

Last close
61.71 usd
Market cap
1.15B usd
52 week high
87.78 usd
52 week low
45.08 usd
Target price
90.17 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
6.1565
Price/Book Value
3.5688
Enterprise Value
1.24B usd
EV/Revenue
6.3257
EV/EBITDA
37.0797

Key financials

Revenue TTM
141.68M usd
Gross Profit TTM
39.05M usd
EBITDA TTM
16.56M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
666.22B usd
Net debt
N/A usd

About

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.
  • Symbol
    237690.KQ
  • Exchange
    KQ
  • Isin
    KR7237690003
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Pharmaceuticals
  • CEO
    Mr. Geun-Jo Im Ph.D.
  • Headquarter
    Seoul
  • Web site
    http://www.stpharm.co.kr
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top